Promising combo for tough leukemia falls short in early trial

This study tested whether adding the drug venetoclax to standard chemotherapy could help more people with secondary acute myeloid leukemia (sAML) achieve remission. sAML is a hard-to-treat blood cancer that often follows other bone marrow diseases. The trial planned to enroll 20 newly diagnosed patients, but was terminated early after only 10 participants. The goal was to see if at least 60% of patients had a complete remission, but the early stop means results are limited.